Cyclic PIP synthetase, activated by tyrosine phosphorylation, combines prostaglandin E with activated inositol phosphate to cyclic PIP, a mediator of insulin action

Experimental and Clinical Endocrinology and Diabetes

Volumn 104, Issue , 1996, Pages 142-143

  Wasner, H K ^a   Amini Hadi Kiashar, H ^a   Gypakis, A ^a   Niktopoulos, A ^a  

^a LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0342714022     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0029-1211622     Document Type: Article

References (5)

1. Wasner HK: Regulation of protein kinase and phosphorprotein phosphatase by cyclic AMP and cyclic AMP antagonist. FEBS Lett 57: 60-63, 1975
2. Wasner HK, Kaufmann R, Lemoine H: Mass spectrometry identification of prostaglandylinositol, the dephosphorylated cyclic AMP antagonist, cyclic PIP. Analusis 20: 171-177, 1992
3. Wasner HK, Salge U, Gebel M: The endogenous cyclic AMP antagonist, cyclic PIP: Its ubiquity, hormone stimulated synthesis and identification as prostaglandylinositol cyclic phosphate. Acta Diabetol 30: 220-232, 1993
4. Wasner HK, Weber S, Partke HJ, Amini-Hadi-Kiashar H: Indomethacin treatment causes loss of insulin action in rats: involvement of prostaglandins in the mechanisms of insulin action. Acta Diabetol 31: 175-182, 1994
5. Park DJ, Min HK, Rhee SG: Inhibition of CD3-linked phospholipase C by phorbol ester and by cyclic AMP is associated with decreased phosphotyrosine and increased phosphoserine contents of PLC-gamma-1. J Biol Chem 267: 1496-1501, 1992